NCM
VYNE icon

Nantahala Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Nantahala Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
40,000
+20,000
+100% +$583K 0.04% 140
2025
Q4 		$580K Buy
+20,000
New +$401K 0.02% 143

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Nantahala Capital Management's VYNE Position: Q1 2026 in Review

Nantahala Capital Management increased its VYNE Therapeutics (VYNE) stake by 100% in Q1 2026, buying an estimated $583K and bringing the position to 40,000 shares worth $1.2M. The position accounts for 0.04% of the portfolio, ranked #140.

Nantahala Capital Management first reported a position in VYNE in Q4 2025 and has held it in 2 quarters since. 42 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Nantahala Capital Management held 40,000 shares of VYNE Therapeutics worth $1.2M as of Q1 2026.
  • Nantahala Capital Management bought 20,000 VYNE Therapeutics shares in Q1 2026, an estimated $583K.
  • VYNE Therapeutics made up 0.04% of Nantahala Capital Management's portfolio in Q1 2026, its #140 holding.
  • Nantahala Capital Management first reported a position in VYNE Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 42 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.